Novartis AG ADR (NYSE: NVS) has a higher price-to-earnings ratio of 15.02x compared to its average ratio. NVS has 36-month beta value of 0.58. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NVS is 1.96B, and currently, short sellers hold a 0.29% ratio of that float. The average trading volume of NVS on August 22, 2024 was 1.32M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NVS) stock’s latest price update
Novartis AG ADR (NYSE: NVS) has experienced a rise in its stock price by 0.25 compared to its previous closing price of 117.61. However, the company has seen a gain of 4.06% in its stock price over the last five trading days. invezz.com reported 2024-08-19 that In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world’s top pharmaceutical companies based on their business and financial risk profiles.
NVS’s Market Performance
NVS’s stock has risen by 4.06% in the past week, with a monthly rise of 7.88% and a quarterly rise of 15.64%. The volatility ratio for the week is 0.78% while the volatility levels for the last 30 days are 1.01% for Novartis AG ADR The simple moving average for the past 20 days is 4.83% for NVS’s stock, with a 15.31% simple moving average for the past 200 days.
Analysts’ Opinion of NVS
Goldman, on the other hand, stated in their research note that they expect to see NVS reach a price target of $120. The rating they have provided for NVS stocks is “Buy” according to the report published on May 30th, 2024.
BMO Capital Markets gave a rating of “Market Perform” to NVS, setting the target price at $114 in the report published on February 23rd of the current year.
NVS Trading at 7.69% from the 50-Day Moving Average
After a stumble in the market that brought NVS to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.13% of gains for the given period.
Volatility was left at 1.01%, however, over the last 30 days, the volatility rate increased by 0.78%, as shares surge +6.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.53% upper at present.
During the last 5 trading sessions, NVS rose by +3.79%, which changed the moving average for the period of 200-days by +26.79% in comparison to the 20-day moving average, which settled at $112.86. In addition, Novartis AG ADR saw 16.77% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVS starting from Kowalski Robert William, who proposed sale 6,566 shares at the price of $111.72 back on Aug 12 ’24. After this action, Kowalski Robert William now owns shares of Novartis AG ADR, valued at $733,572 using the latest closing price.
Stock Fundamentals for NVS
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.74 for the gross margin
The net margin for Novartis AG ADR stands at 0.34. The total capital return value is set at 0.17. Equity return is now at value 21.55, with 9.67 for asset returns.
Based on Novartis AG ADR (NVS), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.55. The debt to equity ratio resting at 0.66. The interest coverage ratio of the stock is 13.14.
Currently, EBITDA for the company is 18.47 billion with net debt to EBITDA at 1.1. When we switch over and look at the enterprise to sales, we see a ratio of 5.22. The receivables turnover for the company is 5.69for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.93.
Conclusion
To put it simply, Novartis AG ADR (NVS) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
